Utility Menu

National Association of Pharmacy Regulatory Authorities

Provinces

Main navigation


Search: National Drug Schedules

Begin your search by using the generic name of the product:

Search by Glossary
Drug Name Comment Schedule Date
EcgonineN I JUN / 02
Econazole and its saltsF1 I SEP / 98
Ecothiophate and its saltsF2 I SEP / 98
Ectylurea and its saltsF1 I SEP / 98
EculizumabF1 I MAR / 11
Edoxaban or its saltsPDL I FEB / 17
Edrophonium chlorideF1 I SEP / 98
EfavirenzF1 I MAY / 00
Eflornithine and its salts and derivativesF1 I JUL / 03
Elbasvir or its saltsPDL I AUG / 16
Electrolyte solutions for oral rehydration III SEP / 98
Eletriptan and its saltsF1 I FEB / 07
Eliglustat or its saltsPDL I MAY / 17
Elosulfase alfaPDL I AUG / 14
ElotuzumabPDL I AUG / 16
Eltrombopag or its saltsPDL

including but not limited to eltrombopag olamine

I DEC / 13
Eluxadoline or its saltsPDL I APR / 17
EmbutramideF1 I SEP / 98
Emedastine and its saltsF1 I SEP / 99
EmpagliflozinPDL I OCT / 15
EmtricitabineF1 I FEB / 07
EmylcamateF1 I SEP / 98
Enalaprilat and its salts and derivativesF1 I SEP / 98
Encephalitis vaccine (Japanese) I FEB / 02
EnestebolC3 I JUN / 02
EnfluraneF1 I SEP / 98
EnfuvirtideF1 I JUN / 06
Enoxaparin and its saltsF1 I SEP / 98
EnrofloxacinF1 I SEP / 98
EntacaponeF1 I JUL / 03
EntecavirF1 I OCT / 07
Ephedrine and its salts in preparations containing more than 8 mg per unit dose, or with a label recommending more than 8 mg/dose or 32 mg/day, or labelled or implied for use exceeding 7 days, or if indicated for other than nasal congestion. I FEB / 02
Ephedrine and its salts in combination products in preparations containing no more than 8 mg per unit dose, with a label recommending no more than 8 mg/dose or 32 mg/day and for use not more than 7 days, and indicated for nasal congestion. III APR / 06
Ephedrine and its salts in single entity products. in preparations containing no more than 8 mg per unit dose, with a label recommending no more than 8 mg/dose or 32 mg/day and for use not more than 7 days, and indicated for nasal congestion. II APR / 06
Epinephrine and its salts in pre-filled syringes intended for emergency administration by injection in the event of anaphylactic reactions to allergens II SEP / 99
Epinephrine and its salts. other than in pre-filled syringes intended for emergency administration by injection in the event of anaphylactic reactions to allergens I SEP / 99
Epirubicine and its saltsF1 I SEP / 98
EpitiostanolC3 I JUN / 02
EplerenonePDL I DEC / 13
EpsiprantelF1 I MAY / 00
Ergot alkaloids and their saltsF2 I SEP / 98
Eribulin or its salts or derivativesPDL

including but not limited to eribulin mesylate

I DEC / 13
Erlotinib and its saltsF1 I OCT / 07
Ertapenem and its saltsF1 I JUN / 06
Erythrityl tetranitrate I SEP / 98
Erythromycin and its salts and derivativesF2 I SEP / 98
ErythropoietinF1 I SEP / 98
Escitalopram and its saltsF1 I FEB / 07
Esdepallethrin/piperonyl butoxide II SEP / 98
Eslicarbazepine acetatePDL I AUG / 14
Esmolol and its saltsF1 I SEP / 98
Esomeprazole or its salts except when sold for the 14-day treatment for frequent heartburn at a daily dose of 20 mg in package sizes of no more than 280 mg of esomeprazole I AUG / 16
Esomeprazole or its salts. when sold for the 14-day treatment for frequent heartburn at a daily dose of 20 mg, in package sizes of no more than 280 mg of esomeprazole II AUG / 16
Estazolam and its saltsTS I SEP / 98
Estramustine and its saltsF1 I SEP / 98
EtanerceptF1 I JUL / 03
Ethacrynic acidF1 I SEP / 98
Ethambutol and its saltsF1 I SEP / 98
Ethanolamine oleate II SEP / 98
EthchlorvynolTS I SEP / 98
EthinamateTS I SEP / 98
Ethionamide and its saltsF1 I SEP / 98
Ethoheptazine and its salts II SEP / 98
Ethomoxane and its saltsF1 I SEP / 98
Ethopropazine hydrochlorideF1 profenamine and its salts I SEP / 98
Ethotoin and its saltsF1 I SEP / 98
Ethyl Chloride except in trace amounts II SEP / 98
Ethyl LoflazepateTS I JUN / 02
Ethyl trichloramateF1 I SEP / 98
EthylestrenolC3 I JUN / 02
EthylmethylthiambuteneN I JUN / 02
EthylmorphineN I JUN / 02
Ethylpapaverine and its salts I SEP / 98
Etidronic acid and its saltsF1 I SEP / 98
Etodolac and its salts and derivativesF1 I SEP / 98
EtonitazeneN I JUN / 02
Etoposide and its derivativesF1 I SEP / 98
EtorphineN I JUN / 02
EtoxeridineN I JUN / 02
Etravirine and its saltsF1 I OCT / 09
EtretinateF1 I SEP / 98
Etryptamine and its saltsF1 I SEP / 98
Etymemazine and its saltsF1 I SEP / 98
EvolocumabPDL I JAN / 16
ExemestaneF1 I DEC / 02
Exenatide or its saltsPDL I DEC / 13
EzetimibeF1 I JUN / 06

87 result(s)


Footnotes

  • C1: Drug is in the Controlled Drugs and Substances Act and Part I of the Schedule to Part G of the Food and Drug Regulations}
  • C2: Drug is in the Controlled Drugs and Substances Act and Part II of the Schedule to Part G of the Food and Drug Regulations
  • C3: Drug is in the Controlled Drugs and Substances Act and Part III of the Schedule to Part G of the Food and Drug Regulations
  • C4: drug is in the Controlled Drugs and Substances Act
  • C5: drug is in the Regulations Under CDSA
  • CR: drug has been recommended for addition to the Controlled Drugs and Substances Act
  • CR-C: drug has been recommended for addition to the Controlled Drugs and Substances Act, Part G of the Food and Drug Regulations
  • CR-N: drug has been recommend for addition to the Controlled Drugs and Substances Act, Narcotic Control Regulations
  • CR-TS: drug has been recommended for addition to the Controlled Drugs and Substances Act, Benzodiazepines and Other Targeted Substances Regulations
  • F1: drug appears in Part I of Schedule F to the Food and Drugs Act and Regulations
  • F2: drug appears in Part II of Schedule F to the Food and Drugs Act and Regulations
  • FR: drug has been recommended for addition to Schedule F to the Food and Drugs Act and Regulations ("Schedule F Recommended")
  • N: drug is in the Narcotic Control Regulations under the Controlled Drugs and Substances Act
  • NR: drug has not been reviewed by NDSAC
  • PDL: drug is in the Prescription Drug List (effective Dec. 19, 2013)
  • R: drug is in Part J of the Food and Drus Act and listed in the Controlled Drugs and Substances Act
  • TS: drug is in the Benzodiazepines and Other Targeted Substances Regulations under the Controlled Drugs and Substances Act
  • U: drug has been reviewed by NDSAC and is unscheduled